# FEB 0 2 2004 BE

# **RECEIVED**

FEB **0 6** 2004

PATENT
Attorney Docket No. 210485
Client Reference No. 20794

## **TECH CENTER 1600/2900**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ikemoto et al.

Group Art Unit: 1625

Application No. 09/824,447

**Examiner: Raymond Covington** 

Filed: April 2, 2001

For:

CITALOPRAM HYDROBROMIDE CRYSTAL AND METHOD FOR CRYSTALLIZATION THEREOF

### INFORMATION DISCLOSURE STATEMENT

RECEIVED

JUN 1 8 2004

TECH CENTER 1600/2900

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing
date of a national application other than a continued prosecution application under
37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as

In re Appln. of Ikemoto et al. Application No. 09/824,447

	of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
$\boxtimes$	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:						
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).						
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).						
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).						
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).  NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.						
Copie	s of the References						
	Copies of the references listed on the enclosed Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).						
	A copy of the foreign search report is enclosed herewith.						
	The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:						

In re Appln. of Ikemoto et al. Application No. 09/824,447

U.S. APPI	LICATIONS	St		
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.				
2.				
3.				

2.								
3.								
Stater	nent under 37 CFR	1.97(e)						
	Information Disclo	hereby states that each sure Statement was fince in a counterpart foreign filing of the Information	rst cited in a gn patent appl	ny commun lication not r	ication from a			
$\boxtimes$	The <b>undersigned</b> hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.							
Stater	nent under 37 CFR	1.704(d)						
	Information Discloration office in a counterpany individual desi	hereby states that each sure Statement was cited part application and that gnated in 37 CFR 1.56(c) Disclosure Statement.	in a communithis commun	ication from a ication was i	a foreign patent not received by			
Fees								
	No fee is owed by the IDS Fee of \$18	he applicant(s). 30 under 37 CFR 1.17(p)	is enclosed he	erewith.				
Metho	od of Payment of Fe	es						
		in the amount of \$ count No. 12-1216 in the is enclosed for that purp		80.00. (A du	plicate copy of			
Autho	orization to Charge	Additional Fees						

### Authorization to Charge Auditional rees

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

In re Appln. of Ikemoto et al. Application No. 09/824,447

### **Instructions as to Overpayment**

Credit Account No. 12-1216. Refund

> John Kilyk, Jr., Reg. No. 38 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780 (312) 616-5600 (telephone)

(312) 616-5700 (facsimile)

Date: January 27, 2004

### **CERTIFICATE OF MAILING**

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

• -	•			T FED	0 2 200	4 발   분/	Comple	te if Knowak	- 3
Substitute for	form 144	9A/B/PTO		13/2	لم	Application Number	09/824,	<del> </del>	20
CMT & TO					TANDEN	Filing Date	April 2,		to m
INFORMATION DISCLOSU					N	First Named Inventor	Ikemoto	( )	5 1
STATEMENT BY APPLI			PLICAN		Group Art Unit	1625	7	5 R	
	(Use	as many sheet	s as ned	essary)		Examiner Name	Raymor	nd Covington	2 2
Sheet	1	1	of	1		Attorney Docket Number	210485		03
		·							
				<del>.</del>	U.S. PA	TENT DOCUMENTS			
		U.S. Pa	atent Do	cument					
Examiner Initials	Doc. No.	Applicatio Patent Nui		Kind Code	1	Name of Patentee or Applicant Liljegren et al.		Date of Publication	Filing Date If Appropriate
	ΑJ	2003/0232	881	A1	Liljegre			Dec. 12, 2003	
						•			

					N PATENT DOCUMENTS			
		Fo	reign Patent Docume	nt			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*
				<del>  </del>				_
		<b> </b>		<b>-</b>				_
		I I		1 1				

OTHER - NON PATENT LITERATURE DOCUMENTS							
Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item					
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+			
	·						
				1			

Examiner Signature	Date Considered	

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).